Changhoon Yoo

9.0k total citations · 1 hit paper
252 papers, 4.2k citations indexed

About

Changhoon Yoo is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Changhoon Yoo has authored 252 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Oncology, 94 papers in Surgery and 90 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Changhoon Yoo's work include Pancreatic and Hepatic Oncology Research (74 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (68 papers) and Gastric Cancer Management and Outcomes (41 papers). Changhoon Yoo is often cited by papers focused on Pancreatic and Hepatic Oncology Research (74 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (68 papers) and Gastric Cancer Management and Outcomes (41 papers). Changhoon Yoo collaborates with scholars based in South Korea, United States and Japan. Changhoon Yoo's co-authors include Baek‐Yeol Ryoo, Min‐Hee Ryu, Kyu‐pyo Kim, Yoon‐Koo Kang, Jae Ho Jeong, Cheolwon Suh, Seung‐Mo Hong, Heung-Moon Chang, Dok Hyun Yoon and Jaekyung Cheon and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Changhoon Yoo

237 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 113 citations Sten Myrehaug, Beth Chasen et al. profile →

Peers

Countries citing papers authored by Changhoon Yoo

Since Specialization

Citations

This map shows the geographic impact of Changhoon Yoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changhoon Yoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changhoon Yoo more than expected).

Fields of papers citing papers by Changhoon Yoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changhoon Yoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changhoon Yoo. The network helps show where Changhoon Yoo may publish in the future.

Co-authorship network of co-authors of Changhoon Yoo

This figure shows the co-authorship network connecting the top 25 collaborators of Changhoon Yoo. A scholar is included among the top collaborators of Changhoon Yoo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changhoon Yoo. Changhoon Yoo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab 2025 ·Journal of Hepatology ·Hyung‐Don Kim, Sun Jin Sym, Hong Jae Chon, (unknown), Jung Hun Kang, Baek‐Yeol Ryoo, Choong‐kun Lee, Joo-Hyun Hong, Hyewon Ryu, (unknown), Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae‐Yong Kim, Changhoon Yoo	3
2	Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer 2025 ·JAMA Network Open ·Hyehyun Jeong, Changhoon Yoo, Il Hwan Kim, Jung Hun Kang, Jae Ho Jeong, Kwonoh Park, (unknown), Inkeun Park, Sun Jin Sym, Jaekyung Cheon, Hyewon Ryu, Jun‐Eul Hwang, (unknown), Baek‐Yeol Ryoo, Kyu‐pyo Kim	0
3	139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC) 2024 ·Annals of Oncology ·(unknown), Richard S. Finn, Changhoon Yoo, Zhenggang Ren, Junji Furuse, Robin Kate Kelley, Stephen L. Chan, Julien Edeline, Heinz‐Josef Klümpen, Thomas Yau, Chris Verslype, Masato Ozaka, Mohamed Bouattour, (unknown), Arndt Vogel, Juan W. Valle, Liis Starkopf, Usha Malhotra, (unknown), Shukui Qin	0
4	211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study 2024 ·Annals of Oncology ·(unknown), Daniel M. Halperin, Sten Myrehaug, (unknown), (unknown), Pamela L. Kunz, Beth Chasen, (unknown), (unknown), D-Y. Oh, Changhoon Yoo, Stephen Falk, (unknown), (unknown), Ying Zhang, (unknown), Diego Ferone	4
5	Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial 2024 ·Nature Medicine ·Hyung‐Don Kim, (unknown), Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, (unknown), Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo	29
6	Identification of Atezolizumab Plus Bevacizumab Prognostic IndexviaRecursive Partitioning Analysis in HCC: The ABE Index 2023 ·Anticancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fabian Finkelmeier, (unknown), (unknown), (unknown), Changhoon Yoo, (unknown), Tiziana Pressiani, (unknown), (unknown), Lorenza Rimassa, (unknown), (unknown), Andrea Casadei‐Gardini, (unknown)	4
7	104P Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA) 2023 ·Annals of Oncology ·Hyehyun Jeong, Kwang Pyo Kim, Jae Ho Jeong, Dae Wook Hwang, Jeong Hyun Lee, KH Kim, (unknown), (unknown), Soo‐Jin Park, Hong Jae Chon, Jin‐hong Park, Jong Soo Lee, B-Y. Ryoo, Changhoon Yoo	1
8	Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis 2023 ·ESMO Open ·Jaewon Hyung, (unknown), (unknown), Shinkyo Yoon, Changhoon Yoo, Yong Sang Hong, Jae Ho Jeong, Tae Won Kim, Seong Woo Jeon, (unknown), Chan Kwon Jung, (unknown), Ji Hoon Kim, Sail Chun, Jin‐Hee Ahn	2
9	Prediction of margin‐negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT‐determined resectability 2022 ·Journal of Hepato-Biliary-Pancreatic Sciences ·Jong Keon Jang, (unknown), Jae Ho Byun, Jin Hee Kim, Seung Soo Lee, Hyoung Jung Kim, Changhoon Yoo, Kyu‐pyo Kim, Seung‐Mo Hong, Dong‐Wan Seo, Dae Wook Hwang, Song Cheol Kim	4
10	Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study 2021 ·Liver Cancer ·Changhoon Yoo, Jwa Hoon Kim, Min‐Hee Ryu, Sook Ryun Park, Danbi Lee, Kang Mo Kim, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Joycelyn Jie Xin Lee, David Tai, Stephen L. Chan, Baek‐Yeol Ryoo	68
11	Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma 2021 ·Liver International ·Won‐Mook Choi, Ji Yoon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Min‐Hee Ryu, Baek‐Yeol Ryoo, Kang Mo Kim	28
12	Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review 2021 ·Cancers ·Changhoon Yoo, Sang Hyun Shin, (unknown), Kyu‐pyo Kim, Jae Ho Jeong, Baek‐Yeol Ryoo, Woohyung Lee, Ki Byung Song, Dae Wook Hwang, Jin‐hong Park, Jae Hoon Lee	12
13	Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma 2021 ·Liver International ·(unknown), Changhoon Yoo, Hyo Jeong Kang, (unknown), Min‐Hee Ryu, Sook Ryun Park, Danbi Lee, Jonggi Choi, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Baek‐Yeol Ryoo	27
14	CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy 2020 ·Cancer Immunology Research ·Hyung‐seung Jin, (unknown), (unknown), (unknown), Dong-Hee Lee, (unknown), Inki Kim, Hee Jin Lee, Eun Kyung Choi, Kyu‐pyo Kim, Changhoon Yoo, Yoon Park	62
15	Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study 2020 ·Liver International ·Hyung‐Don Kim, (unknown), Myung Ah Lee, Jin Won Kim, Jee Hyun Kim, Hong Jae Chon, Beodeul Kang, Myoung Joo Kang, Il Hwan Kim, Jaekyung Cheon, Jun‐Eul Hwang, Jung Hun Kang, Seonggyu Byeon, Jung Yong Hong, Baek‐Yeol Ryoo, Ho Yeong Lim, Changhoon Yoo	34
16	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events 2020 ·Liver International ·Changhoon Yoo, Seonggyu Byeon, (unknown), Jaekyung Cheon, Jin W. Kim, Jeeho Kim, Hong Jae Chon, Beodeul Kang, Myoung Joo Kang, Il Hwan Kim, Jun‐Eul Hwang, Jung Hun Kang, Myung A. Lee, Jung Yong Hong, Ho Yeong Lim, Baek‐Yeol Ryoo	31
17	Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score 2020 ·Radiology ·Dong Wook Kim, Seung Soo Lee, Seon‐Ok Kim, Jin Hee Kim, Hyoung Jung Kim, Jae Ho Byun, Changhoon Yoo, Kyu‐pyo Kim, Ki Byung Song, Song Cheol Kim	31
18	Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinoma 2020 ·Journal of Hepato-Biliary-Pancreatic Sciences ·(unknown), SoJung Lee, Jae Hoon Lee, Seung‐Mo Hong, Seo Young Park, Changhoon Yoo, Woohyung Lee, Ki Byung Song, Dae Wook Hwang, Song Cheol Kim	4
19	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis 2019 ·Cancers ·Changhoon Yoo, Sang Hyun Shin, Kyu‐pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Jun Kang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung‐Hwan Kim, Jin‐hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Baek‐Yeol Ryoo, Song Cheol Kim	34
20	Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib 2010 ·Journal of Clinical Oncology ·Changhoon Yoo, Min‐Hee Ryu, Byung Woog Kang, Shinkyo Yoon, Baek‐Yeol Ryoo, Heung-Moon Chang, Jae‐Lyun Lee, (unknown), (unknown), Yoon‐Koo Kang	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact